rhIGF-1 (recombinant human insulin-like growth factor-1) is made by Tercica Pharmaceuticals (Increlex) as a treatment for 'short stature' due to severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. (rhIGF-1 is also known as mecasermin)
provided by;
NLM (Pubmed) search results for 'mecasermin' and 'rhIGF-1'
Clinicaltrials.gov search results for 'mecasermin' and 'rhIGF-1'
Tercica - Increlex (mecasermin [rDNA origin] for injection - "rhIGF-1")
Big Pharmaceutical Companies - caveat emptor!